Betagenon Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

Betagenon General Information

Description

Developer of AMP-activated protein kinase (AMPK) activator compounds based in Umea, Sweden. The company is a biopharmaceutical specialisit that focuses on the development of AMPK activator compounds, to treat chronic energy balance disorders and diseases in metabolically challenged elderly and obese individuals.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Västra Strandgatan 9B
  • 903 26 Umea
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Västra Strandgatan 9B
  • 903 26 Umea
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Betagenon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Betagenon‘s full profile, request access.

Request a free trial

Betagenon Patents

Betagenon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026117736-A1 Combination therapies Pending 27-Nov-2024
WO-2025252672-A1 Use of tryptophan and metabolites thereof as biomarkers for treatment methods Pending 03-Jun-2024
JP-2026531750-A Cancer treatment with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazole-5-yl)benzamide Pending 03-Aug-2023
EP-4753704-A1 Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide Pending 03-Aug-2023
WO-2025027205-A1 Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide Inactive 03-Aug-2023 A61K31/433
To view Betagenon’s complete patent history, request access »

Betagenon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Betagenon Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Betagenon‘s full profile, request access.

Request a free trial

Betagenon FAQs

  • When was Betagenon founded?

    Betagenon was founded in 2001.

  • Where is Betagenon headquartered?

    Betagenon is headquartered in Umea, Sweden.

  • What is the size of Betagenon?

    Betagenon has 1 total employees.

  • What industry is Betagenon in?

    Betagenon’s primary industry is Drug Discovery.

  • Is Betagenon a private or public company?

    Betagenon is a Private company.

  • What is the current valuation of Betagenon?

    The current valuation of Betagenon is .

  • What is Betagenon’s current revenue?

    The current revenue for Betagenon is .

  • How much funding has Betagenon raised over time?

    Betagenon has raised $5M.

  • Who are Betagenon’s investors?

    Fort Knox, Ivy Capital (Shanghai), MCG Global Technology, and The Kempe Foundations have invested in Betagenon.

  • When was Betagenon acquired?

    Betagenon was acquired on 14-Mar-2023.

  • Who acquired Betagenon?

    Betagenon was acquired by Amplifier Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process